Tr1X
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4242 Campus Point Ct Ste 500, San Diego,...Phone Number
(858) 255-4447Website
tr1x.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tr1X
Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, including the scientists behind the discovery of Tr1 cells, the company's pipeline of universal allogeneic cell therapies is being developed for diseases with high unmet medical need. The company is headquartered in San Diego, has developed a robust intellectual property portfolio,Explore more
Tr1X Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tr1X your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Tr1X has new funding data
Earning: See what the market has to say on Tr1X recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tr1X launches new products
Check out if Tr1X is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Tr1X
Click to see if Tr1X had a recent Job posting/layoffs
Tr1X, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Tr1X has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Tr1X
Find more new buyers
Compare Similar Companies to Tr1X
Compare insights from companies similar to Tr1X, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tr1X is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tr1X is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tr1X.
Tr1X financials insights
Gather financial insights about Tr1X, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$75M
Tr1X Tech Stack
A closer look at the technologies used by Tr1X
Most Recent Scoops
Open Position
Person-Based
Facilities Relocation / Expansion
Tr1X is planning to move offices in November 2025. The move will impact approximately 20 employees at the existing office located at 4242 Campus Point Court, Suite #500, San Diego, CA.
Facilities Relocation/Expansion
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Open Position
Tr1X News & Media
CIRM awards $8m grant to Tr1X for trial of GvHD prevention drug candidate TRX103
The California Institute for Regenerative Medicine (CIRM) has given $8m to biotechnology company Tr1X to support its trial of TRX103.Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in theTr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced a planned leadership transition in which co-founder and Chief Operating Officer David de Vries will succeed Bill Lis as Chief Executive Officer, effective June 1, 2025. Mr. Lis will become Executive Chairman of the BoTr1X to Participate at Upcoming Healthcare Investment Conferences
SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company specializing in allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced the attendance and participation of select members of the management team at the following upcoming investor conferences:
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Tr1X
Sign Up For FreeTo access detailed company insights
Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, including the scientists behind the discovery of Tr1 cells, the company's pipeline of universal allogeneic cell therapies is being developed for diseases with high unmet medical need. The company is headqua... Read More
